Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Protagonist Therapeutics, Inc.”

32 pharma patents match "Protagonist Therapeutics, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 32
Index total 30,257
Page 2 / 2

Quick answer

This filtered view shows 32 pharmaceutical patents matching "Protagonist Therapeutics, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

32 results for “Protagonist Therapeutics, Inc.” · 30,257 patents in full index Clear search

  1. US 10030061

    Hepcidin analogues and uses thereof

    Protagonist Therapeutics, Inc. · Granted Jul 24, 2018 · Expires Jul 19, 2038

    granted
  2. US 10023614

    Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

    Protagonist Therapeutics, Inc. · Granted Jul 17, 2018 · Expires Jul 12, 2038

    granted
  3. US 9822157

    Hepcidin analogues and uses thereof

    Protagonist Therapeutics, Inc. · Granted Nov 21, 2017 · Expires Nov 16, 2037

    granted
  4. US 9809623

    α4β7 peptide monomer and dimer antagonists

    Protagonist Therapeutics, Inc. · Granted Nov 7, 2017 · Expires Nov 2, 2037

    granted
  5. US 9714270

    a4B7 integrin thioether peptide antagonists

    Protagonist Therapeutics, Inc. · Granted Jul 25, 2017 · Expires Jul 20, 2037

    granted
  6. US 9624268

    Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

    Protagonist Therapeutics, Inc. · Granted Apr 18, 2017 · Expires Apr 13, 2037

    granted
  7. US 9518091

    A4B7 peptide monomer and dimer antagonists

    Protagonist Therapeutics, Inc. · Granted Dec 13, 2016 · Expires Dec 8, 2036

    granted
  8. US 9273093

    α4β7 peptide dimer antagonists

    Protagonist Therapeutics, Inc. · Granted Mar 1, 2016 · Expires Feb 25, 2036

    granted